Resistance of human immunodeficiency virus type 1 to reverse transcriptase and protease inhibitors: Genotypic and phenotypic testing

Journal of Clinical Virology

Volumn 21, Issue 3, 2001, Pages 197-212

  Garcia Lerma G ^a   Heneine, W ^a  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

Genotype; HIV 1 drug resistance; Phenotype

Indexed keywords

ABACAVIR; AMPRENAVIR; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; DELAVIRDINE; DIDANOSINE; EFAVIRENZ; INDINAVIR; LAMIVUDINE; NELFINAVIR; NEVIRAPINE; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; ZALCITABINE; ZIDOVUDINE;

CELL CULTURE; CONFERENCE PAPER; DRUG RESISTANCE; DRUG SENSITIVITY; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; IN VITRO STUDY; LYMPHOCYTE; PHENOTYPE; POINT MUTATION; PRIORITY JOURNAL; SEQUENCE ANALYSIS; TECHNIQUE; VIRUS ISOLATION; VIRUS MUTATION; VIRUS REPLICATION;

ANTI-HIV AGENTS; DRUG RESISTANCE, MICROBIAL; GENOTYPE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; MUTAGENESIS; REVERSE TRANSCRIPTASE INHIBITORS;

EID: 0034985186     PISSN: 13866532     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1386-6532(00)00163-3     Document Type: Article

References (110)

1. Mechanisms of nucleoside analog antiviral activity and resistance during human immunodeficiency virus reverse transcription
2. Sensitive detection and quantification of particle-associated reverse transcriptase in plasma of HIV-1-infected individuals by the product-enhanced reverse transcriptase (PERT) assay
3. High level resistance to (-) enantiomeric 2-deoxy-3′-thiacytidine in vitro is due to one amino acid substitution in the catalytic site of human immunodeficiency virus type 1 reverse transcriptase
4. Persisting long-term benefit of antiretroviral genotypic guided treatment for HIV-infected patients failing on HAART: the viraclapt study, week 48 follow up
5. 2′-deoxy-3′-thiacytidine is a potent, highly selective inhibitor of human immunodeficiency virus type 1 and type 2 replication in vitro
6. In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors
7. 1592U89, a novel carbocyclic nucleoside analog with potent, selective anti-human immunodeficiency virus activity
8. Nevirapine, zidovudine, and didanosine compared with zidovudine and didanosine in patients with HIV-1 infection. A randomized, double-blind, placebo-controlled trial. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group Protocol 241 Investigators
9. Insertion of two amino acids combined with changes in reverse transcriptase containing tyrosine-215 of HIV-1 resistant to multiple nucleoside analogs
10. Replication of a pre-existing resistant HIV-1 sub population in vivo after introduction of a strong selective drug pressure
11. HIV-1 drug susceptibilities and reverse transcriptase mutations in patients receiving combination therapy with didanosine and delavirdine
12. HIV-1 group O sensitivity to antiretroviral drugs
13. Susceptibility of human immunodeficiency virus type 1 group O isolates to antiretroviral agents: in vitro phenotypic and genotypic analysis
14. Quasispecies structure and persistance of RNA viruses
15. Quasispecies: the concept and the word
16. Viral quasispecies and the problem of vaccine-escape and drug-resistant mutants
17. A mutation in reverse transcriptase of bis (heteroaryl) piperazineresistant human immunodeficiency virus type 1 that confers increased sensitivity to other nonnucleoside inhibitors
18. U-90152, a potent inhibitor of human immunodeficiency virus type 1 replication
19. Drug-resistance genotyping in HIV-1 therapy: the VIRADAPT randomized controlled trial
20. Identifying and characterizing HIV protease inhibitors
21. Measurement of human immunodeficiency virus type 1 plasma virus load based on reverse transcriptase (RT) activity: evidence of variabilities in levels of virion-associated RT
22. A rapid non-culture-based assay for clinical monitoring of phenotypic resistance of human immunodeficiency virus type 1 to lamivudine (3TC)
23. Quantitation of human immunodeficiency virus type 1 group O in plasma by measuring reverse transcriptase activity
24. Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HI-1 in Kampala, Uganda: HIVNET 012 randomized trial
25. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy
26. AIDS Clinical Trials Group 320 Study Team. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic milliliter or less
27. Significance of aminoacid variation of human immunodeficiency virus type 1 reverse transcriptase residue 210 for zidovudine susceptibility
28. Resistance profile of the human immunodeficiency virus type 1 reverse transcriptase inhibitor abacavir (1592U89) after monotherapy and combination therapy. CNA2001 Investigative Group
29. Nevirapine-resistant human immunodeficiency virus: kinetics of replication and estimated prevalence in untreated patients
30. A pilot study to evaluate the development of resistance to nevirapine in asymptomatic human immunodeficiency virus-infected patients with CD4 cell counts >500/mm3: AIDS Clinical Trial Group Protocol 208
31. Detection of reverse transcriptase by a highly sensitive assay in sera from persons infected with human immunodeficiency virus type 1
32. A novel human immunodeficiency virus type 1 reverse transcriptase mutational pattern confers phenotypic lamivudine resistance in the absence of mutation 184V
33. A rapid method for simultaneous detection of phenotypic resistance to inhibitors of protease and reverse transcriptase in recombinant human immunodeficiency virus type 1 isolates from patients treated with antiretroviral drugs
34. Antiretroviral drug resistance testing in adult HIV-1 infection: recommendations of an international AIDS society-USA panel
35. Characterization of human immunodeficiency virus type 1 variants with increased resistance to C2-symmetric protease inhibitor
36. An in vivo mutation from leucine to tryptophan at position 210 in human immunodeficiency virus type 1 reverse transcriptase contributes to high-level resistance to 3′-azido-3′-deoxythymidine
37. Structure of a covalently trapped catalytic complex of HIV-1 reverse transcriptase: implications for drug resistance
38. Multidrug-resistant human immunodeficiency virus type 1 strains resulting from combination antiretroviral therapy
39. Standardized peripheral blood mononuclear cell culture assay for determination of drug susceptibilities of clinical human immunodeficiency virus type 1 isolates
40. Non nucleoside reverse transcriptase inhibitors
41. Viracept (nelfinavir mesylate, AG1343): a potent orally bioavailable inhibitor of HIV-1 protease
42. Recombinant virus assay: a rapid, phenotypic assay for assessment of drug susceptibility of human immunodeficiency virus type 1 isolates
43. Zidovudine treatment results in the selection of human immunodeficiency virus type 1 variants whose genotypes confer increasing levels of drug resistance
44. Genetic polymorphisms near HIV-1 reverse transcriptase resistance-associated codons is a major obstacle for the line probe assay as an alternative method to sequence analysis
45. Active human immunodeficiency virus protease is required for viral infectivity
46. Emergence of multi-dideoxynucleoside-resistant human immunodeficiency virus type 1 variants, viral sequence variation, and disease progression in patients receiving antiretroviral chemotherapy
47. Comparative fitness of multidideoxynucleoside-resistant human immunodeficiency virus type 1 (HIV-1) in an in vitro competitive HIV-1 replication assay
48. Didanosine resistance in HIV-infected patients switched from zidovudine to didanosine monotherapy
49. Mutagenic study of codons 74 and 215 of the human immunodeficiency virus type 1 reverse transcriptase, which are significant in nucleoside analog resistance
50. Novel mutation (V75T) in human immunodeficiency virus type 1 reverse transcriptase confers resistance to 2′,3′-didehydro-2′,3′-dideoxythymidine in cell culture
51. Susceptibilities of zidovudine-susceptible and-resistant human immunodeficiency virus isolates to antiviral agents by using a quantitative plaque reduction assay
52. Multiple mutations in HIV-1 reverse transcriptase confer highlevel resistance to zidovudine (AZT)
53. Potential mechanism for sustained antiretroviral efficacy of AZT+3TC combination therapy
54. A family of insertion mutations between codons 67 and 70 of human immunodeficiency virus type 1 reverse transcriptase confer multinucleoside analog resistance
55. In vivo sequence diversity of the protease of human immunodeficiency virus type 1: presence of protease inhibitor-resistant variants in untreated subjects
56. Stavudine resistance: an update on susceptibility following prolonged therapy
57. Potent and selective in vitro activity of 3′-deoxythymidin-2′-ene (3′-deoxy-2′,3′-didehydrothymidine) against human immunodeficiency virus
58. Impact of drug resistance mutations on virologic response to salvage therapy
59. Altered drug sensitivity, fitness, and evolution of human immunodeficiency virus type 1 with pol gene mutations conferring multidideoxynucleoside resistance
60. Resistance to nevirapine of HIV-1 reverse transcriptase mutants: loss of stabilizing interactions and thermodynamic or steric barriers are induced by different single amino acid substitutions
61. Lower in vivo mutation rate of human immunodeficiency virus type 1 than that predicted from the fidelity of purified reverse transcriptase
62. Replicative fitness of protease inhibitor-resistant mutants of human immunodeficiency virus type 1
63. Inhibition of the in vitro infectivity and cytopathic effect of human T-lymphotrophic virus type III/lymphadenopathy-associated virus (HTLV-HI/LAV) by 2′,3′-dideoxynucleosides
64. 3′-azido-3′-deoxythymidine (BW A509U): and antiviral agent that inhibits the infectivity and cytopathic effect of human T-lymphotropic virus type III/lymphadenopathy-associated virus in vitro
65. A randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients. The INCAS trial
66. Natural occurrence of drug resistance mutations in the reverse transcriptase of human immunodeficiency virus type 1 isolates
67. Pol gene quasispecies of human immunodeficiency virus: mutations associated with drug resistance in virus from patients undegoing no drug therapy
68. In vitro selection and characterization of human immunodeficiency virus type 1 (HIV-1) isolates with reduced sensitivity to hydroxyethylarnino sulfonamide inhibitors of HIV-1 aspartyl protease
69. Role of human immunodeficiency virus type 1-specif protease in core protein maturation and viral infectivity
70. HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time
71. A novel phenotypic drug susceptibility assay for human immunodeficiency virus type 1
72. Reservoirs for HIV-1: mechanisms for viral persistence in the presence of antiviral immune responses and antiretroviral therapy
73. Comparison of line probe assay (LIPA) and sequence analysis for detection of HIV-1 drug resistance
74. Ultrasensitive retrovirus detection by a reverse transcriptase assay based on product-enhancement
75. Nevirapine resistance mutations of human immunodeficiency virus type 1 selected during therapy
76. Human immunodeficiency virus type 1 mutants to nonnucleoside inhibitors of reverse transcriptase arise in tissue culture
77. Rational design of peptidebased HIV proteinase inhibitors
78. Characterization of human immunodeficiency viruses resistant to oxatiolate-cytosine nucleosides
79. Multiple drug resistance to nucleoside analogs and nonnucleoside reverse transcriptase inhibitors in an efficiently replicating human immunodeficiency virus type 1 strain
80. Multiple dideoxynucleoside analogue-resistant (MddNR) HIV-1 strains isolated from patients from different European countries
81. Worldwide evaluation of DNA sequencing approaches for identification of drug resistance mutations in the human immunodeficiency virus type 1 reverse transcriptase
82. Combination therapy with zidovudine and didanosine selects for drug-resistant human immunodeficiency virus type 1 strains with unique patterns of pol gene mutations
83. AIDS Clinical Trials Group 143 Virology Team. Drug resistance and heterogeneous long-term virologic responses of human immunodeficiency virus type 1-infected subjects to zidovudine and didanosine combination therapy
84. Changes in drug sensitivity of human immunodeficiency virus type 1 during therapy with azidothymidine, dideoxycytidine, and dideoxyinosine: an in vitro comparative study
85. Emergence of human immunodeficiency virus type 1 variants with resistance to multiple dideoxynucleosides in patients receiving therapy with dideoxynucleosides
86. An RT-PCR assay for the enzyme activity of reverse transcriptase capable of detecting single virions
87. Mechanisms of inhibition of HIV-1 reverse transcriptase by nonnucleoside inhibitors
88. Resistance to ddI and sensitivity to AZT induced by a mutation in HIV-1 reverse transcriptase
89. Line probe assay for rapid detection of drug-selected mutations in human immunodeficiency virus type 1 reverse transcriptase gene
90. Line probe assay for detecting mutations in HIV-1 reverse transcriptase
91. Rapid in vitro selection of human immunodeficiency virus type 1 resistant to 3′-thiacytidine inhibitors due to a mutation in the YMDD region of the reverse transcriptase
92. Enzymatic characterization of human immunodeficiency virus type 1 reverse transcriptase resistant to multiple 2′, 3′-dideoxynucleoside 5′- triphosphates
93. L-735,524: an orally bioavailable human immunodeficiency virus type 1 protease inhibitor
94. Patients HIV-1 strains carrying the multiple nucleoside resistance mutations are crossresistant to abacavir
95. Rapid screening of phenotypic resistance to nevirapine by direct analysis of HIV type 1 reverse transcriptase activity in plasma
96. A 6-basepair insert in the reverse transcriptase gene of human immunodeficiency virus type 1 confers resistance to multiple nucleoside inhibitors
97. Activity of non-nucleoside reverse transcriptase inhibitors against HIV-2 and SIV
98. A novel dipyridodiazepinone inhibitor of HIV-1 reverse transcriptase acts through a non substrate binding site
99. Highly sensitive qualitative and quantitative detection of reverse transcriptase activity: optimization, validation, and comparative analysis with other detection systems
100. In vivo activity against HIV and favorable toxicity profile of 2′,3′-dideoxyinosine
101. L-743, 726 (DN4P-266): a novel, highly potent nonnucleoside inhibitor of the human immunodeficiency virus type 1 reverse transcriptase
102. Resistance to 2′,3′-dideoxycytidine conferred by a mutation in codon 65 of the human immunodeficiency virus type 1 reverse transcriptase